Companies › Geron
1 active drug program in 3 registered trials: 1 Phase 3, 1 Phase 2, 1 Phase 1; Hematology, Oncology; next expected readout Feb 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Imetelstat sodium Telomerase reverse transcriptase inhibitor | TERT | Phase 3 | Myelofibrosis; Myelodysplastic Syndromes | Feb 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT02598661 | Imetelstat sodium | Phase 2 | Myelodysplastic Syndromes | Hematology | Oct 2023 |
| NCT05371964 | Imetelstat sodium | Phase 1 | Myelofibrosis | Oncology | Feb 2027 |
| NCT04576156 | Imetelstat sodium | Phase 3 | Myelofibrosis | Oncology | Jun 2028 |
Cash of $69m on 2026-09-30; operating cash outflow about $92m a year; runway about 9 months at that burn, to Jul 2027; 0 of 1 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
–
Servier Affaires Médicales Karyopharm Therapeutics Can-Fite BioPharma LeonaBio RenovoRx
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.